FDA panel backs Puma's neratinib, clearing path to approval | Fierce Biotech
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Neratinib maleate (HKI-272 maleate) | HER2/EGFR Inhibitor | MedChemExpress
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity (NASDAQ:PBYI) | Seeking Alpha
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
Marketing Application for Early Stage Breast Cancer Therapy Neratinib Submitted to EMA by Puma Biotechnology - Breast Cancer News
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | SpringerLink
NERATINIB, HKI 272, ..Puma presents positive results from phase II trial of its investigational drug PB272 | New Drug Approvals
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
Puma Biotechnology Surging
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
U.S. Food and Drug Administration Approves Puma's NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Earl
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
SABCS 2022: A phase 1b study of neratinib with THP in metastatic and locally advanced breast cancer, and phase II study of THP followed by AC in HER2 + primary inflammatory breast
Puma Biotechnology
EX-99.1
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
Nerlynx: Package Insert - Drugs.com
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | The Motley Fool
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
Nerlynx (neratinib) Cancer Medication - Cancer Health
